These findings underscore that E2F1-responsive lncRNAs-derived immunogenic peptides can bind to MHC class I complex and be engineered as cancer vaccines that trigger the CD8 T cell-mediated adaptive immune response, providing remarkably therapeutic benefits. The gene discussed is CD8A; the disease is cancer.